Category Archives: Evergreening

Healthcare Groups Challenge Patents On Three New Hep-C Drugs In India

Source: Business World The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices Patient and healthcare aid groups, including I-MAK and Delhi Network of … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

Healthcare and patient groups oppose patents on crucial hepatitis C drugs

By Rupali Mukherjee, The Times of India  MUMBAI: Healthcare aid and patient groups have come together in patent courts to fight against “abusive strategies” of Big Pharma, to ensure access to affordable treatment in hepatitis C. The Initiative for Medicines, … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , | Leave a comment

Flawed patents on hepatitis C drugs latest to be challenged in global push for access

Source: MSF Access Campaign New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. … Continue reading

Posted in Evergreening, Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Tagged , , | Leave a comment

TPP is dead, but its legacy lives on

By Arjun Jayadeva, The HinduThe Hindu | February 9, 2017 The Trans-Pacific Partnership was dead long before Donald Trump signed his executive order. But its damaging aspects, like stringent IP provisions, have just migrated to other agreements U.S. President Donald Trump’s … Continue reading

Posted in Data Exclusivity, Evergreening, Patent Term Extension, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment

Demonstrations held at Roche & pharma associations in South Africa, Malaysia, UK, France, Zambia, Brazil, US

Source: TAC Tuesday, 7th February 2017 –* Swiss multinational company Roche faced global condemnation today from women living with cancer, families of people with cancer, activists, scientists, researchers and health professionals from across the world. They highlighted the immoral and unconscionable tactics employed by … Continue reading

Posted in Cancer, Evergreening, Patent, Uncategorized | Leave a comment

India to US: Will not tighten IPR rules beyond TRIPS mandate

Commerce Minister Nirmala Sitharaman demands food safety clearance mechanism during talks with US Trade Representative Source: The Hindu BusinessLine | October 20, 2016 India and the US continued to differ on the issue of intellectual property rights (IPR) norms at … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR, Patent linkage, Sec 3 (d), TRIPS, TRIPS plus, Uncategorized, UNHLP report, USTR 301 report | Leave a comment

TPP and the Dire Threat to Affordable Drug Prices

Drug prices in the U. S. are already approaching a crisis point for many patients unable to afford their prices, often despite being insured. These examples indicate how serious this problem has become:  The use of prescription drugs by Americans, … Continue reading

Posted in Evergreening, TPP, Uncategorized | Leave a comment